文献速递骨质疏松与钙磷/甲状旁腺

散发性原发性甲状旁腺功能亢进患者的异常组蛋白甲基化谱

Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该研究采用组蛋白H3多重免疫分析,比较散发性甲状旁腺腺瘤(PA,n=30)、非典型甲状旁腺肿瘤(APT,n=5)、甲状旁腺癌(PC,n=5)与对照外周血及组织样本的组蛋白修饰谱,并用Western blot验证。结果显示抑制性H3K27me3升高、H3K4me3与H3K36me3降低,提示转录抑制偏移,通路富集涉及钙信号、Wnt与Hippo通路。

要点

  • 甲状旁腺肿瘤中H3K27me3在血液和组织中升高,提示转录抑制增强。
  • H3K4me3与H3K36me3在APT和PC中降低,经Western blot验证。
  • 钙信号、Wnt与Hippo通路可能与组蛋白H3修饰相关。

核心结论

  • 散发性甲状旁腺肿瘤中抑制性H3K27me3升高、H3K4me3和H3K36me3降低,整体向转录抑制偏移。
  • 识别这些修饰的功能机制可能为甲状旁腺肿瘤治疗靶点提供新思路。

研究设计与样本

  • 研究对 sporadic PA(n=30)、APT(n=5)、PC(n=5)及对照的血液和组织样本行组蛋白H3多重免疫分析比较修饰谱。
  • 差异修饰经Western blot验证,并与临床病理特征作相关性分析,另行通路富集分析。

主要发现

  • 血液和组织中H3K4与H3K36三甲基化降低(<60%),H3K27三甲基化和H3K9单甲基化升高(>130%)。
  • Western blot示APT与PC的H3K4me3低于对照(0.5 ± 0.4 vs 4.4 ± 0.7,P = .02;0.4 ± 0.2 vs 4.4 ± 0.7,P = .004)。
  • Western blot示APT与PC的H3K36me3低于对照(0.4 ± 0.2 vs 1.0 ± 0.3,P = .03;0.2 ± 0.1 vs 1.0 ± 0.3,P = .02)。
  • H3K27me3在PA(2.9 ± 1.2 vs 1.1 ± 0.21,P = .04)、APT(4.2 ± 2.9 vs 1.1 ± 0.21,P = .007)和PC(6.9 ± 3.1 vs 1.1 ± 0.21,P = .0002)均高于对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Primary hyperparathyroidism (PHPT) is a systemic endocrine disorder characterized by elevated PTH levels and hypercalcemia. Gene-specific epigenetic modifications like histone methylation play a pivotal role in PHPT by altering expression of parathyroid-specific genes. However, global histone modifications in parathyroid tumors and their implications for tumor behavior remain underexplored. EXPERIMENTAL DESIGN: We performed comparative histone modification profiling in blood and tissue samples from sporadic parathyroid adenomas (PA; n = 30), atypical parathyroid tumors (APT; n = 05), and parathyroid carcinomas (PC; n = 05) along with controls using histone H3 multiplex immunoassay. Significantly dysregulated modifications were validated by Western blotting (WB), and expression data was correlated with clinicopathological features. We performed pathway enrichment analysis to elucidate molecular pathways potentially linked to histone H3 modifications in parathyroid tumorigenesis. RESULTS: We observed dynamic alterations in histone H3 modifications of lysine (K) residues across parathyroid tumor phenotypes in blood and tissue samples. A reduction in H3K4 and H3K36 trimethylation (<60%) and an increase in H3K27 trimethylation and H3K9 monomethylation (>130%) compared to controls was observed. WB confirmed lower H3K4me3 (0.5 ± 0.4 vs 4.4 ± 0.7, P = .02; 0.4 ± 0.2 vs 4.4 ± 0.7, P = .004) and H3K36me3 (0.4 ± 0.2 vs 1.0 ± 0.3, P = .03; 0.2 ± 0.1 vs 1.0 ± 0.3, P = .02) in APT and PC than controls and higher H3K27me3 expression in PA (2.9 ± 1.2 vs 1.1 ± 0.21, P = .04), APT (4.2 ± 2.9 vs 1.1 ± 0.21, P = .007), and PC (6.9 ± 3.1 vs 1.1 ± 0.21, P = .0002) relative to controls. Pathway enrichment analysis identified molecular pathways, including calcium signaling, Wnt, and Hippo signaling, associated with histone H3 modifications. CONCLUSION: Increased expression of repressive H3K27me3 in blood and tissue samples, while decreased H3K4me3 and H3K36me3, suggest a shift toward transcriptional repression. Identifying their functional mechanisms may facilitate the discovery of novel insights for therapeutic targeting in parathyroid tumors.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kumari P, Bhadada SK, Arya AK, et al. Aberrant Histone Methylation Profile in Patients with Sporadic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2026. PMID: 41396875. doi:10.1210/clinem/dgaf668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。